XRF-1021

XRF-1021 is an orally active HIPK2 inhibitor with an IC50 value of 0.18 μM. It reduces the expression of fibrosis markers such as fibronectin, type I collagen, and α-SMA in NRK-49F and HK-2 cells stimulated by TGF-β1. XRF-1021 blocks signaling pathways including TGF-β, NF-κB, p53, Wnt/β-catenin, and Notch. Additionally, it alleviates renal injury and fibrosis in vivo and can be utilized for research in chronic kidney disease.